anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is a prospective, open label, single arm, single center study. The objective is to study the safety of the RejuvenAir System in a population of subjects who are scheduled to undergo a planned lobectomy. A secondary objective is to determine the histological effects of RejuvenAir System treatment in the airways. The Primary Endpoint is Safety as measured by occurrence of serious adverse events related to metered dose radial spray cryotherapy treatment performed prior to scheduled lobectomy surgery. The patient population intended to participate in this study are subjects scheduled to undergo lobectomy for peripheral lung lesions suspicious for or known to be cancer. Secondarily, this will enable an understanding of the histological characteristics and healing outcomes post-treatment in the airways, which will be resected. CSA Medical has conducted bench and animal studies that support the use of the RejuvenAir System as sufficiently safe and effective to warrant advancing the product into this primary safety study in patients presenting for consideration of lobectomy. Such patients provide a safe population to further the clinical evaluation of the system in that these subjects will receive their lobectomy or procedure 2 to 14 days following delivery of their metered liquid nitrogen treatment. At the time of their metered liquid nitrogen treatment they will be in an operating room setting with their thoracic surgeon in attendance. It is anticipated that subjects who agree to participate in this study will have the metered liquid nitrogen treatment at the time of evaluation of their lung lesion. This evaluation will include bronchoscopy with ultrasound for evaluation of their lymph nodes prior to the planned surgical resection of their lung abnormality.
FIELD: medical engineering. SUBSTANCE: device has sublayer and (a) echogenic superficial layer containing echogenic structures composed of pores, pockets, craters, and/or cavities. The echogenic structures are open for material under study and entrap and hold gas; and/or (b) have substrate containing non-gaseous material near the surface. When heated, the material produces gas bubbles so that the entrapped gas or one produced when heating contributes to increased visibility in carrying out ultrasonic examination. EFFECT: enhanced effectiveness of visualization when applying biomedical examination devices. 24 cl, 2 tbl
Systems and methods are provided for determining patient adherence to a medication protocol by evaluating healthcare transactions. An e-prescription transaction can be received from a prescriber and evaluated to determine if the patient is to receive adherence analysis. If so, the e-prescription data can be stored and the e-prescription can be forwarded to a pharmacy. A healthcare claim transaction for a medication can be received from the pharmacy and forwarded on for adjudication. If approved, the claim transaction data can be evaluated to determine if it matches any stored e-prescription data records. Upon identifying a match, a prescription fill status notification can be generated and transmitted to the prescriber computer associated with the prescriber of the medication in the e-prescription. If the healthcare claim transaction is for a refill or a maintenance medication, a patient adherence level can be calculated and included in the prescription fill status notification.
The diagnosis of Chiari I malformation is straightforward in patients with typical signs and symptoms of Chiari I malformation and magnetic resonance imaging (MRI) confirming ≥5 mm of cerebellar tonsillar ectopia, with or without a syrinx. However, in many cases, Chiari I malformation is discovered incidentally on MRI to evaluate global headache, cervical radiculopathy, or other conditions. In those cases, the clinician must consider if cerebellar tonsillar ectopia is related to the presenting symptoms. Surgical decompression of the cerebellar tonsils and foramen magnum in patients with symptomatic Chiari I malformation effectively relieves suboccipital headache, reduces syrinx distension, and arrests syringomyelia progression. Neurosurgeons must avoid operative treatments decompressing incidental tonsillar ectopia, not causing symptoms. Such procedures unnecessarily place patients at risk of operative complications and tissue injuries related to surgical exploration. This chapter reviews the typical signs and symptoms of Chiari I malformation and its variant, Chiari 0 malformation, which has <5 mm of cerebellar tonsillar ectopia and is often associated with syringomyelia. Chiari I and Chiari 0 malformations are associated with incomplete occipital bone development, reduced volume and height of the posterior fossa, tonsillar ectopia, and compression of the neural elements and cerebrospinal fluid (CSF) pathways at the foramen magnum. Linear, angular, cross-sectional area, and volume measurements of the posterior fossa, craniocervical junction, and upper cervical spine identify morphometric abnormalities in Chiari I and Chiari 0 malformation patients. Chiari 0 patients respond like Chiari I patients to foramen magnum decompression and should not be excluded from surgical treatment because their tonsillar ectopia is <5 mm. The authors recommend the adoption of diagnostic criteria for Chiari 0 malformation without syringomyelia. This chapter provides updated information and guidance to the physicians managing Chiari I and Chiari 0 malformation patients and neuroscientists interested in Chiari malformations.
The present invention relates to a natural composition for preventing and treating Parkinson disease and, more specifically, to a composition for preventing and treating Parkinson disease by using extracts of a sclerotium of Poria cocas Wolf, a root of Paeonia lactiflora Pallas, an Atractylodes japonica Koidz, a Cnidium officinale Makino, and a Sapium sebiferum Roxb, etc. which are natural plants. Provided in the present invention is a natural composition having functions of preventing and treating Parkinson disease composed by mixing extracts of a sclerotium of Poria cocas Wolf, a root of Paeonia lactiflora Pallas, an Atractylodes japonica Koidz, a Cnidium officinale Makino, and a Sapium sebiferum Roxb, etc. And, provided in the present invention is a natural composition having functions of preventing and treating Parkinson disease, which is characterized by being a decocted composition. And, provided in the present invention is a natural composition having functions of preventing and treating Parkinson disease, which is characterized by being a herbal acupuncture composition. And, provided is a natural composition having functions of preventing and treating Parkinson disease, which is characterized by being composed by mixing 50-150 parts of a root of Paeonia lactiflora Pallas, 50-150 parts by weight of an Atractylodes japonica Koidz, 50-150 parts by weight of Cnidium officinale Makino, and 50-150 parts by weight of a Sapium sebiferum Roxb.
The invention relates to a hop yeast tabletting candy and a preparation method thereof. The hop yeast tabletting candy is prepared from the raw materials in parts by mass: 15 to 20 parts of hop, 10 to 18 parts of chromium-riched yeast, 75 to 80 parts of filler, 1 to 2 parts of lubricating agent, and 5 to 10 parts of adhesion agent. The preparation method comprises the steps of adopting the hop and the chromium-riched yeast as main functional components, mixing with the filler and the adhesion agent in proportion, using a boiling dryer for pelletizing, and then adding the lubricating agent for tabletting into tablets. The preparation method provided by the invention adopts a one-step pelletizing method, so that the production efficiency is high. The prepared tabletting candy has delicate taste and pleasant hop aroma and yeast aroma, is convenient to carry and eat, can be used for assisting to reduce blood glucose of a diabetic patient, reduce serum cholesterol and improve endocrine, has a remarkable prevention and curative effect on prostatitis, prostate cancer and other prostate diseases, and further has a certain adjuvant therapy efficacy on diseases such as breast cancer and colon cancer at the same time. The preparation method is simple in steps, convenient to operate, and high in practicability.
The investigators will use an assessment and treatment decision schema that has been successful in restoration of life role participation for stroke survivors and a comparable schema used for cognitive training for TBI patients. The subject assessment and decision schema will be used to identify for each subject, the optimal array of impairment interventions. The proposed treatment will optimize outcome by customizing the intervention and use of technologies, while ensuring the application of the array of impairment interventions required to produce restoration of function and life role participation. The investigators will target an array of impairments preventing participation in life role activities, which will include dyscoordination and weakness of upper limb, impaired balance, gait deficits, and impaired attention and executive function. In treatment, the investigators will use a dual-task paradigm combining motor and cognitive training, with treatment extending to the every day environment. Treatment will be up to 5 times/wk, 5hrs/day for 12 weeks.
NEW MATERIAL:The dibenzoxazepine derivative of formula I (R is H or lower alkyl; n is 1-5) and its salt. EXAMPLE:4-(2-Chlorodibenz[b,f][1,4]oxazepin-11-yl)-1-piperazinepropionic acid ethyl ester. USE:It has antidepressant, antianxiety, analgesic, antiemetic, gastroenteric motion promoting, antiarrhythmic, hypotensive or anti-allergic actions and is useful as a drug. PREPARATION:The objective compound of formula I can be produced by reacting amoxapine of formula II with a halogen compound of formula III (X is halogen) in a solvent or in the absence of solvent at 0-100 deg.C in the presence of a base as an acid acceptor. The base is e.g. sodium hydroxide or potassium carbonate and the reaction solvent is e.g. methanol or acetone.
Study setting and financial support: data for the present investigation were obtained from an ongoing epidemiological and three-year longitudinal intervention program of first-episode psychosis (PAFIP) conducted at the outpatient clinic and the inpatient unit at the University Hospital Marqués de Valdecilla, Spain. Conforming to international standards for research ethics, this program was approved by the local institutional review board. Patients meeting inclusion criteria and their families provided written informed consent to be included in the PAFIP. The Mental Health Services of Cantabria provided funding for implementing the program. No pharmaceutical company supplied any financial support.

Study design: this is a flexible-dose study of two neuroleptics (Aripiprazole and Risperidone) assigned at aleatory ratio 1:1. Rapid titration schedule (5-day), until optimal dose is reached, is a rule used unless severe side effects occur. At the treating physician's discretion, the dose and type of antipsychotic medication could be changed based on clinical efficacy and the profile of side effects during the follow-up period. Antimuscarinic medication, Lormetazepam and Clonazepam are allowed for clinical reasons. No antimuscarinic agents are administered prophylactically. Antidepressants (Sertraline) and mood stabilizers (lithium) are permitted if clinically needed.

Clinical assessment: the severity scale of the Clinical Global Impression (CGI) scale, the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Positive symptoms (SAPS), the Scale for the Assessment of Negative symptoms (SANS), the Calgary Depression Scale for Schizophrenia (CDSS) and the Young Mania Rating Scale (YMRS) were used to evaluate symptomatology. To assess general adverse event experiences, the Scale of the Udvalg for Kliniske Undersogelser (UKU), the Simpson-Angus Rating Scale (SARS) and the Barnes Akathisia Scale (BAS) were used. The same trained psychiatrist (BC-F) completed all clinical assessments. These clinical data are described at AZQ2005 study.

Neuropsychological assessment. Cognitive functioning was assessed in patients at 2 points: baseline and 3 years after the initialization of antipsychotic treatment. The cognitive assessment at baseline was carried out at 12 weeks after recruitment because this time is considered optimal for patients' stabilization. The evaluation required approximately 2 h and was carried out in the same day by the same neuropsychologist (R.A.-A and E.G.-R). The neuropsychological battery comprises 9 cognitive domains: information processing speed, motor dexterity, working memory, verbal learning, visuospatial abilities, delayed memory, attention, executive function and theory of mind.
BACKGROUND: Status Epilepticus (SE) leads to the development of epilepsy with the contribution of Endoplasmic Reticulum (ER) stress. Uridine, a pyrimidine nucleoside, has been shown to have neuroprotective and antiepileptogenic effects in animal models. This study aimed to determine whether uridine ameliorates ER stress and apoptosis following epileptogenic insult. Secondly, this study aimed to establish the effect of uridine on inflammatory and oxidative stress parameters that contribute to ER stress.
METHODS: Status epilepticus was induced using lithium-pilocarpine in adult male Sprague-Dawley rats. Following SE termination, rats were treated with uridine, 4-phenylbutyric acid (4-PBA), or saline twice daily for 48 h. Expressions of hippocampal glucose-regulated protein 78 (GRP78), Inositol- Requiring Protein 1 (IRE1α), Protein kinase RNA-like Endoplasmic Reticulum Kinase (PERK), and C/EBP Homologous Protein (CHOP) were determined by western blotting 48 h after SE. Uridine's effects on apoptosis, inflammation or oxidation were evaluated by analyses of cleaved caspase-3 and poly(ADP-ribose) polymerase 1 (PARP1) protein expressions or pro-inflammatory cytokine levels or levels of oxidative stress markers, respectively.
RESULTS: Expressions of all ER stress-related proteins significantly increased 48 h after SE. Uridine treatment markedly decreased GRP78, IRE1α, and CHOP levels. A decrease in the PERK level was observed following the administration of 4-PBA; however, uridine had no effect. Cleaved caspase-3 and PARP1 levels were increased in the SHAM group, while uridine and 4-PBA treatment effectively decreased their expressions. Treatment with uridine significantly reduced Myeloperoxidase (MPO) and Malondialdehyde (MDA) levels while tending to increase Catalase (CAT) and Glutathione Peroxidase (GPx) levels. Uridine treatment also significantly attenuated levels of TNF-α and IL-1β, the pro-inflammatory cytokines, which increased 48 h post-SE.
CONCLUSION: Our data indicate that uridine alleviates ER stress after SE. This effect may be attributed to the regulation of inflammation and oxidative stress. Uridine shows promise as a potential preventive agent for epilepsy.
Participants will receive 10-session intervention of sham stimulation (sham cTBS followed by sham iTBS, with an interval of 10 minutes). The stimulation will be delivered 3-5 sessions per week, lasting for 2-3 weeks. Participants will receive a 60-minute standard robot-assisted training after each stimulation session.
Patients randomized to the Control Group will receive blood component therapy guided by conventional coagulation tests per usual clinical practice. The control arm involves the use of conventional coagulation tests (aPTT, INR, fibrinogen level, D-dimer) to diagnose and describe post-injury coagulopathy and to guide blood product replacement. In the Control Group, blood will be drawn for conventional coagulation testing (aPTT, INR, platelet count, fibrinogen level, D-dimer) at Baseline (as defined above), then twice more during the first six hours at the discretion of the treating team, then again at 12 hours and at 24 hours post-injury. The current institutional massive transfusion protocol will be followed. Only the results pertinent to the group to which randomized will be released to the treating team, unless otherwise requested.
Paederosidic acid (PA) has shown beneficial effects in anti-inflammatory studies, but it is unclear whether PA has positive impacts on bone loss induced by lipopolysaccharide (LPS). This study aims to investigate the influence of PA on bone loss in LPS-treated rats. The study assesses changes in the viability and osteogenic potential of MC3T3-E1 cells, as well as osteoclast differentiation in RAW264.7 cells in the presence of LPS using CCK-8, ALP staining, AR staining, and Tartrate-resistant acid phosphatase (TRAP) staining. In vitro experiments indicate that LPS-induced inhibition of osteoclasts (OC) and Superoxide Dismutase 2 (SOD2) correlates with heightened levels of inflammation and oxidative stress. Furthermore, PA has demonstrated the ability to alleviate oxidative stress and inflammation, enhance osteogenic differentiation, and suppress osteoclast differentiation. Animal experiments also show that PA significantly upregulates SOD2 expression while downregulating TNF-α expression (all, p < 0.05), leading to the restoration of impaired bone metabolism, improved bone strength, and increased bone mineral density (all, p < 0.05), compared to the control group. The collective experimental findings strongly suggest that PA can enhance osteogenic activity in the presence of LPS by reducing inflammation and oxidative stress, hindering osteoclast differentiation; hence mitigating bone loss in LPS-treated rat models.
Packaging an acne packet, which packet will hold just one three inch by three inch square acne pad is disclosed. The three inch square acne pad is folded in half twice to render the size of the acne pad one and one-half inches by one and one-half inches. The, folded pad is thereafter inserted by a packet forming machine utilizing MP3850 paper, foil, and poly carbonate to render the packaged pad ultimately three inches by two and three-quarters by one-eighth to one-quarter inch thick with twenty-two individual packets separated at their lateral edges and then placed in a box. The acne pad itself is 75 gram 149-189 tight waffle Novonette. Each pad is impregnated with 1.56 grams of the treatment solution. The method of forming the pads is to run the three inch ribbon of waffle Novonette through a feeding machine and thereafter dip the same in a solution having as its most active ingredient 0.5% salicylic acid. De-ionized water (75%) and SD Alcohol 40 (24%) make up the major portion of the inactive ingredient.
This is a randomized double-blind placebo controlled 8 week outpatient medication clinical trial to evaluate the relative efficacy of High-Dose (42mg) versus Regular Dose (21mg) nicotine patch treatment for individuals with schizophrenia or schizoaffective disorder and nicotine dependence. It also has a placebo controlled continuation phase to examine if longer duration of treatment is more effective than a standard eight week dosing schedule. The literature supports that schizophrenics have an increased rates of smoking and are more likely to be dependent on nicotine. Nicotine gum and patches are safe and now approved for over the counter sale in the United States. High dose patch therapy is well tolerated and provides more complete nicotine replacement. This improves withdrawal symptom relief and it is hypothesized that abstinence rates from smoking will be greater in the high dose patch group. Few trials have examined the usefulness of nicotine replacement therapy in this population and preliminary evidence shows lower than expected success rates of smoking cessation with conventional treatments
Patients complete questionnaires and participate in interview over 30 minutes. Patients also undergo collection of medical data and blood, tissue, and stool samples.
Achieving Change Through Values-Based Behavior (ACTV) - pronounced "ACTIVE" - is a new Batterers Intervention Program (BIP) for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is an innovative BIP in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming.
Forward head posture and temporomandibular disorder are two common problems in post-pubertal females. They are closely related to each other. Previous studies showed influences of head posture on the mandibular rest position, range of functional movements and the jaw and neck muscles work together during rhythmic movements. They affirm that patients with TMD present more alterations in head positioning than patients with no dysfunction .

However, no studies up to date has been evaluated the effect of FHP on TMJ proprioception. The proprioceptors in the human TMJ play important key role in identification of mandibular position when the teeth are not occluded. TMJ receptors provide the greater afferent activity regarding perceptual awareness of joint position and movement . Proper assessment of TMJ proprioception may be critical for designing not only rehabilitation but also pre-habilitation interventions for patients with FHP aiming to prevent TMD. Therefore, this study will be the first one which aims to investigate the effect of FHP on TMJ proprioception in post-pubertal females. This study may expand the role of physiotherapy in woman's health.
Lung cancer stands as one of the most lethal diseases and is the foremost cause of cancer-related mortalities worldwide. The pathophysiology of lung cancer is multifaceted, and it includes multiple cell signaling pathways and other complex factors such as oxidative stress and genetics. The association of HPV with lung carcinogenesis was first proposed in 1979, and since then, scientists worldwide have been putting forward several hypotheses to establish a relationship between this virus and lung cancer. Although studies have reported the presence of HPV in lung cancer, the exact mechanism of entry and the route of transmission have not been elucidated clearly till date. Numerous studies across the globe have detected differentially expressed HPV oncoproteins in lung cancer patients and found their association with the critical cell signaling pathways that leads to the development and progression of lung cancer. Many reports have also provided evidence stating the involvement of HPV in determining the survival status of lung cancer patients. The present review recapitulates the studies evincing the association of HPV and lung cancer, its route of transmission and mechanism of action; the detection of the virus and treatment opportunities for HPV-positive lung cancer; and the severity associated with this disease. Therefore, this will provide an explicit idea and would help to develop preventive measures and specific as well as effective treatment for HPV-associated lung carcinogenesis.
The diagnosis of LC was based on clinical, laboratory, and radiological analyses, and/or liver biopsies. PVT was diagnosed according to the consensus for management of PVT in LC (2020, Shanghai) \[1\]. The inclusion criteria were as follows: (I) age ≥18 years, (II) Doppler ultrasound was the first-choice imaging modality; however, enhanced computed tomography or magnetic resonance imaging could also be used for confirmation at the time of admission to our hospital, and (III) patients with PVT on imaging examination but with insufficient evidence for the diagnosis of cirrhosis, hepatic vein pressure gradient measurement, and liver biopsy. Patients with primary or secondary hepatic malignant tumors, other malignant tumors, hematologic diseases, Budd-Chiari syndrome, non-cirrhotic PVT, inflammatory diseases, and other severe diseases were excluded.